Novartis receives positive CHMP opinion for first-line use of Zykadiaź
Novartis announced the Committee for Medicinal Products for Human Use of the EMA has recommended approval of expanding the use of Zykadiaź (ceritinib) to include first-line treatment of patients with advanced non-small cell lung cancer whose tumors are ALK-positive. May 19, 2017
